Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRTS NASDAQ:NVNO NASDAQ:NYXH NASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRTSAlpha Tau Medical$3.04-0.7%$3.03$1.93▼$4.39$259.55M0.9949,356 shs35,232 shsNVNOenVVeno Medical$4.97-5.3%$3.99$2.03▼$5.92$92.06M0.93115,802 shs360,024 shsNYXHNyxoah$8.22-0.7%$7.59$5.55▼$11.87$282.02M1.6276,748 shs11,372 shsSMTISanara MedTech$26.31-4.2%$29.42$25.86▼$39.08$244.06M1.329,863 shs51,685 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRTSAlpha Tau Medical-0.33%-2.86%+3.38%+19.07%+45.02%NVNOenVVeno Medical+22.95%+21.53%+22.38%+114.29%-11.76%NYXHNyxoah+3.89%+6.98%+6.98%+37.31%-10.00%SMTISanara MedTech-1.54%-10.47%-1.29%-6.69%-8.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRTSAlpha Tau Medical3.1743 of 5 stars3.55.00.00.03.31.70.0NVNOenVVeno Medical0.4982 of 5 stars0.02.00.00.02.70.80.6NYXHNyxoah2.5663 of 5 stars3.53.00.00.02.70.80.6SMTISanara MedTech2.1651 of 5 stars3.51.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRTSAlpha Tau Medical 3.00Buy$8.00163.16% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ANYXHNyxoah 3.00Buy$14.5076.40% UpsideSMTISanara MedTech 3.00Buy$49.5088.14% UpsideCurrent Analyst Ratings BreakdownLatest NVNO, DRTS, NYXH, and SMTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $53.004/29/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/21/2025NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRTSAlpha Tau MedicalN/AN/AN/AN/A$0.89 per shareN/ANVNOenVVeno MedicalN/AN/AN/AN/A$2.40 per shareN/ANYXHNyxoah$4.89M57.25N/AN/A$3.60 per share2.28SMTISanara MedTech$86.67M2.70N/AN/A$4.45 per share5.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRTSAlpha Tau Medical-$31.75M-$0.46N/AN/AN/AN/A-49.48%-36.69%8/13/2025 (Estimated)NVNOenVVeno Medical-$21.82M-$1.18N/AN/AN/AN/A-51.32%-48.23%7/30/2025 (Estimated)NYXHNyxoah-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.34N/AN/AN/A-12.48%-29.22%-13.20%8/13/2025 (Estimated)Latest NVNO, DRTS, NYXH, and SMTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DRTSAlpha Tau Medical-$0.12N/AN/AN/AN/AN/A8/13/2025Q2 2025SMTISanara MedTech-$0.33N/AN/AN/A$25.15 millionN/A8/5/2025Q2 2025NYXHNyxoah-$0.60N/AN/AN/A$1.33 millionN/A7/30/2025N/ANVNOenVVeno Medical-$0.28N/AN/AN/AN/AN/A5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million5/14/2025Q1 2025SMTISanara MedTech-$0.31-$0.41-$0.10-$0.41$23.48 million$23.43 million4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRTSAlpha Tau MedicalN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRTSAlpha Tau Medical0.105.815.81NVNOenVVeno MedicalN/A23.7723.77NYXHNyxoah0.223.593.35SMTISanara MedTech1.182.772.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRTSAlpha Tau Medical2.65%NVNOenVVeno Medical34.71%NYXHNyxoahN/ASMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipDRTSAlpha Tau Medical39.50%NVNOenVVeno Medical16.00%NYXHNyxoah17.11%SMTISanara MedTech42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataNVNOenVVeno Medical3017.54 million14.73 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableSMTISanara MedTech608.89 million5.10 millionNot OptionableNVNO, DRTS, NYXH, and SMTI HeadlinesRecent News About These CompaniesSanara MedTech (NASDAQ:SMTI) Stock Price Down 1.5% - Here's WhyJuly 18 at 3:07 AM | marketbeat.comSanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025July 15 at 4:32 PM | globenewswire.comSanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot ProgramJuly 14, 2025 | globenewswire.comSanara MedTech: Pursuing Rapid Expansion While Debt Levels ClimbJune 9, 2025 | seekingalpha.comSanara MedTech Shares Down, Investors Sought For Pilot ProgramMay 15, 2025 | marketwatch.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (SMTI) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comSanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) | SMTI Stock NewsMay 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | investing.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | globenewswire.comWith 31% ownership, Sanara MedTech Inc. (NASDAQ:SMTI) insiders have a lot riding on the company's futureMay 6, 2025 | uk.finance.yahoo.comSanara MedTech Inc. to Report Q1 2025 Financial Results on May 14, 2025April 23, 2025 | quiverquant.comQSanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025April 23, 2025 | globenewswire.comSanara MedTech to Present at Investor ShowcaseApril 22, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVNO, DRTS, NYXH, and SMTI Company DescriptionsAlpha Tau Medical NASDAQ:DRTS$3.04 -0.02 (-0.65%) Closing price 03:58 PM EasternExtended Trading$3.13 +0.09 (+2.96%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.enVVeno Medical NASDAQ:NVNO$4.97 -0.28 (-5.33%) Closing price 04:00 PM EasternExtended Trading$5.04 +0.08 (+1.51%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Nyxoah NASDAQ:NYXH$8.22 -0.06 (-0.72%) Closing price 04:00 PM EasternExtended Trading$8.18 -0.04 (-0.49%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Sanara MedTech NASDAQ:SMTI$26.31 -1.15 (-4.19%) Closing price 04:00 PM EasternExtended Trading$26.37 +0.06 (+0.23%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
